Essential thrombocytosis - Revision history

ClaireLewis at 00:27, 1 October 2019

2019-10-01T00:27:52Z

@@ Línea 1: / Línea 1: @@
 ==Background==
-*Rare, chronic myeloproliferative neoplasm
+*Rare, chronic [[myeloproliferative disorders|myeloproliferative neoplasm]]
 *Abnormal proliferation is seen in megakaryocytic line only
 *Typically in elderly
@@ Línea 6: / Línea 6: @@
 ==Clinical Features==
-*Leukocytosis
+*[[Leukocytosis]]
-*Anemia
+*[[Anemia]]
 *Splenomegaly
-*Clotting or bleeding
+*Clotting or [[coagulopathy|bleeding]]
 ==Differential Diagnosis==
@@ Línea 15: / Línea 15: @@
 *[[Chronic myelogenous leukemia]] (CML)
 *[[Polycythemia vera]] (PV)
 ==Evaluation==
@@ Línea 40: / Línea 75: @@
 ==Management==
-*ASA 81mg
+*[[ASA]] 81mg
-*Myelosuppressive agents (hydroxyurea, interferon alpha)
+*Myelosuppressive agents ([[hydroxyurea]], Interferon-α)
 *Anagrelide

Mholtz: Text replacement - "* " to "*"

2017-07-10T19:59:52Z

Text replacement - "* " to "*"

← Revisión anterior		Revisión del 19:59 10 jul 2017
Línea 6:		Línea 6:

	==Clinical Features==		==Clinical Features==
	* Leukocytosis		*Leukocytosis
	* Anemia		*Anemia
	* Splenomegaly		*Splenomegaly
	* Clotting or bleeding		*Clotting or bleeding

	==Differential Diagnosis==		==Differential Diagnosis==

Rossdonaldson1: /* Also See */

2017-03-20T20:26:30Z

Also See

← Revisión anterior		Revisión del 20:26 20 mar 2017
Línea 43:		Línea 43:
	*Myelosuppressive agents (hydroxyurea, interferon alpha)		*Myelosuppressive agents (hydroxyurea, interferon alpha)
	*Anagrelide		*Anagrelide

			==Disposition==

	==Also See==		==Also See==

Unenthusiastic: /* Management */

2017-03-15T23:36:02Z

Management

← Revisión anterior		Revisión del 23:36 15 mar 2017
Línea 42:		Línea 42:
	*ASA 81mg		*ASA 81mg
	*Myelosuppressive agents (hydroxyurea, interferon alpha)		*Myelosuppressive agents (hydroxyurea, interferon alpha)
			*Anagrelide

	==Also See==		==Also See==

Unenthusiastic: /* EvaluationTefferi, A, et al. The 2008 World Health Organization classification system for myeloproliferative neoplasms: order out of chaos. Cancer. 2009; 115(17):3842-7, */

2017-03-15T23:35:07Z

EvaluationTefferi, A, et al. The 2008 World Health Organization classification system for myeloproliferative neoplasms: order out of chaos. Cancer. 2009; 115(17):3842-7,

← Revisión anterior		Revisión del 23:35 15 mar 2017
Línea 24:		Línea 24:

	===Evaluation<ref>Tefferi, A, et al. The 2008 World Health Organization classification system for myeloproliferative neoplasms: order out of chaos. Cancer. 2009; 115(17):3842-7,</ref>===		===Evaluation<ref>Tefferi, A, et al. The 2008 World Health Organization classification system for myeloproliferative neoplasms: order out of chaos. Cancer. 2009; 115(17):3842-7,</ref>===
	*Criteria: ~~All category A~~		Per the WHO guidelines, diagnosis of ET requires all of the following:

	{\| class="wikitable"		{\| class="wikitable"
	\|-		\|-
	! ~~Category A~~		! Major criteria
	\|-		\|-
	\| Thrombocytosis ≥ 450 x 10<sup>9</sup>L		\| Thrombocytosis ≥ 450 x 10<sup>9</sup>L
Línea 38:		Línea 38:
	\| No evidence of reactive thrombocytosis or presence of JAK2V617F or other clonal marker		\| No evidence of reactive thrombocytosis or presence of JAK2V617F or other clonal marker
	\|}		\|}

	==Management==		==Management==
	*ASA 81mg		*ASA 81mg

Unenthusiastic: /* Clinical Features */

2017-03-15T23:34:15Z

Clinical Features

← Revisión anterior		Revisión del 23:34 15 mar 2017
Línea 6:		Línea 6:

	==Clinical Features==		==Clinical Features==
	* ~~leukocytosis~~		* Leukocytosis
	* ~~anemia~~		* Anemia
	* ~~splenomegaly~~		* Splenomegaly
			* Clotting or bleeding

	==Differential Diagnosis==		==Differential Diagnosis==

Unenthusiastic at 23:33, 15 March 2017

2017-03-15T23:33:00Z

← Revisión anterior		Revisión del 23:33 15 mar 2017
Línea 30:		Línea 30:
	\|-		\|-
	\| Thrombocytosis ≥ 450 x 10<sup>9</sup>L		\| Thrombocytosis ≥ 450 x 10<sup>9</sup>L
			\|-
	\| Megakaryocyte proliferation with little to no granulocyte or erythroid proliferation		\| Megakaryocyte proliferation with little to no granulocyte or erythroid proliferation
	\|-		\|-
	\| Not meeting criteria for CML, PV, PMF, MDS or other myeloid neoplasm		\| Not meeting criteria for CML, PV, PMF, MDS or other myeloid neoplasm
	\|-		\|-
	\| no evidence of reactive thrombocytosis or presence of JAK2V617F or other clonal marker		\| No evidence of reactive thrombocytosis or presence of JAK2V617F or other clonal marker
	\|}		\|}
	==Management==		==Management==

Unenthusiastic: Created page with "==Background== Rare, chronic myeloproliferative neoplasm Abnormal proliferation is seen in megakaryocytic line only Typically in elderly Generally asymptomatic ==Clinical..."

2017-03-15T23:32:01Z

Created page with "==Background== *Rare, chronic myeloproliferative neoplasm *Abnormal proliferation is seen in megakaryocytic line only *Typically in elderly *Generally asymptomatic ==Clinical..."

Página nueva

==Background==
*Rare, chronic myeloproliferative neoplasm
*Abnormal proliferation is seen in megakaryocytic line only
*Typically in elderly
*Generally asymptomatic

==Clinical Features==
* leukocytosis
* anemia
* splenomegaly

==Differential Diagnosis==
*[[Myelofibrosis]]
*[[Chronic myelogenous leukemia]] (CML)
*[[Polycythemia vera]] (PV)

==Evaluation==
===Workup===
*CBC
*Chem 7
*ESR
*Bone marrow biopsy sometimes needed

===Evaluation<ref>Tefferi, A, et al. The 2008 World Health Organization classification system for myeloproliferative neoplasms: order out of chaos. Cancer. 2009; 115(17):3842-7,</ref>===
*Criteria: All category A

{| class="wikitable"
|-
! Category A
|-
| Thrombocytosis ≥ 450 x 10<sup>9</sup>L
| Megakaryocyte proliferation with little to no granulocyte or erythroid proliferation
|-
| Not meeting criteria for CML, PV, PMF, MDS or other myeloid neoplasm
|-
| no evidence of reactive thrombocytosis or presence of JAK2V617F or other clonal marker
|}
==Management==
*ASA 81mg
*Myelosuppressive agents (hydroxyurea, interferon alpha)

==Also See==

==References==
<references/>

[[Category:Heme/Onc]]